Revised FDA draft guidance for generic peptide products updates expectations for ANDAs, impurities, structure, immune response, and biological activity.
The FDA generic peptide guidance was updated with a more detailed regulatory pathway for manufacturers seeking approval of generic versions of complex peptide medicines.
The 28 July 2026 update covers 17 revised draft product-specific guidances and it introduces updated expectations for how applicants demonstrate sameness, quality, and therapeutic equivalence.
Image
FDA Generic Peptide Guidance Expands Scope
The U.S. Food and Drug Administration (FDA) published revised draft product-specific guidances (PSGs) for 17 peptide products, including semaglutide, tirzepatide, liraglutide, glucagon, teriparatide, pegcetacoplan, and vosoritide.
Several are medicines used in areas including obesity, type 2 diabetes, osteoporosis, and macular degeneration.
The timing is hugely significant. Peptides are a really growing and important part of the pharmaceutical market, while demand for generic competition is increasing.
The FDA uses PSGs to give generic developers product-specific recommendations for abbreviated new drug applications (ANDAs).
The objective is to make development and regulatory review more predictable while ensuring generics meet the required standards for safety, effectiveness, quality, and therapeutic equivalence.
However, this specific update really matters beyond the individual products listed.
Five Areas for Peptides Now Matter More
The revised PSGs update FDA recommendations across five areas:
Manufacturing origin: Applicants can address peptides produced recombinantly, synthetically, or semi-synthetically through an ANDA where the applicable recommendations support that route.
Innate immune response: Developers may need to assess whether differences between products could trigger an unwanted immune response.
Impurities: The FDA provides updated expectations around impurity thresholds and characterisation.
Higher-order structure: Applicants need to consider structural characteristics beyond basic sequence and composition.
Biological activity: Developers need evidence that the proposed generic performs appropriately from a biological perspective.
The shift is important because peptide sameness cannot always be reduced to confirming an amino acid sequence.
The FDA’s earlier synthetic peptide guidance already recognised that manufacturing processes can produce peptide-related impurities involving amino acid sequence or residue changes, with potential implications for immunogenicity, safety, or effectiveness.
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
FDA Generic Peptide Guidance Centralises Quality of Evidence
For generic peptide developers, the revised FDA approach places greater emphasis on demonstrating that a proposed product is sufficiently comparable to its reference listed drug.
That means regulatory strategy must connect manufacturing process, analytical characterisation, impurity control, structural assessment, and biological performance.
What matters for development teams is that analytical methods cannot be treated as a final submission exercise. They need to support the evidence package throughout development.
The approach also reflects a wider FDA trend towards more scientifically specific regulatory frameworks. Pharmatica’s analysis of the FDA gene editing guidance examined a similar move towards clearer technical expectations for advanced therapies.
GLP-1 Generics Face Particular Attention
The inclusion of semaglutide and tirzepatide makes the update especially significant.
These medicines have become major products in obesity and metabolic disease, creating substantial commercial interest in future generic competition.
The revised PSGs cover both Ozempic and Wegovy for semaglutide, and Mounjaro and Zepbound for tirzepatide.
An FDA workshop on the generic GLP-1 pathway is also planned for September 2026. The programme will address critical quality attributes, manufacturing considerations, evidence for recombinant and synthetic generic peptides, and drug-device combination products.
The FDA Retires an Older Peptide Framework
The agency is also withdrawing its May 2021 guidance on ANDAs (Abbreviated New Drug Applications) for certain highly purified synthetic peptide products that refer to listed drugs of recombinant DNA origin.
The FDA says that guidance no longer reflects its current scientific thinking and plans to revise it during 2026. That is more than an administrative change.
The draft guidance shows that the FDA is actively updating its peptide framework as scientific understanding, manufacturing technologies, and global regulatory approaches evolve.
Pharmatica has tracked a similar pattern in the FDA’s broader regulatory modernisation agenda, including its drug manufacturing registration proposals, where regulatory requirements are being reconsidered alongside changes in manufacturing technology and supply chains.
What Generics and Peptide Developers Should Watch from the FDA
The FDA is raising the level of scientific detail expected when demonstrating that generic peptide products are equivalent to their reference products.
That could improve regulatory predictability while also making high-quality analytical, structural, impurity, and biological and clinical evidence increasingly important to competitive generic development.
The revised draft PSGs are not final regulations. The FDA will consider comments before finalising them.
The agency also says that recommendations may be relevant to other generic peptide products, with developers encouraged to engage the Office of Generic Drugs through formal meetings or controlled correspondence where appropriate.
For the industry, the immediate priority is therefore regulatory readiness rather than assuming final requirements.
Teams developing generic peptides should monitor the final PSGs, assess their analytical and manufacturing strategies against the revised recommendations, and engage regulators early where product-specific questions remain.
At Pharmatica, we track the regulatory systems shaping pharmaceutical development, manufacturing, and commercialisation. Our Insights connect FDA policy, scientific evidence, and industry strategy so decision-makers can understand where regulatory change creates new opportunities and requirements.
Pharmatica: Insight. Connection. Impact.
Image
Frequently Asked Questions
What is the FDA generic peptide guidance?
The FDA generic peptide guidance consists of 17 revised draft product-specific guidances (PSGs) published on 28 July 2026. They provide product-specific recommendations for developing generic versions of selected peptide medicines and preparing ANDAs.
Which generic peptide products are covered by the revised FDA guidance?
The revised PSGs cover 17 peptide products, including semaglutide, tirzepatide, liraglutide, glucagon, teriparatide, pegcetacoplan, calcitonin salmon, dasiglucagon hydrochloride, and vosoritide. The products include medicines used for obesity, type 2 diabetes, osteoporosis, macular degeneration, and other conditions.
What are the five key areas in the 2026 FDA generic peptide guidance?
The 2026 revised PSGs address five areas: Manufacturing origin, innate immune response testing, impurity thresholds, higher-order structure, and biological activity. The recommendations consider peptides produced through recombinant, synthetic, and semi-synthetic processes.
Why is higher-order structure important for generic peptide products?
Higher-order structure provides information about how a peptide’s molecular structure extends beyond its basic sequence. The FDA has included higher-order structure assessment among the areas developers should consider when establishing the scientific basis for generic peptide products.
Are the FDA’s revised generic peptides guidances final?
No. The documents are revised draft product-specific guidances, so they represent FDA’s current recommendations but are not finalised requirements. FDA will consider public comments before finalising the PSGs. The agency also says that developers working on other generic peptide products can contact the Office of Generic Drugs through a formal meeting request or controlled correspondence.
Nicole (BSc Molecular Medicine, Honours Medical Biochemistry) has many years of pharmaceutical experience, having worked for top CROs and biopharma companies for more than a decade.
Did you enjoy the content?
3
Why not support
Nicole Dale
by giving this content a like
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
Anthropic’s Gates Foundation Partnership and Healthcare AI
See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.
AI in Healthcare: OpenAI and Epic Integration Connects EHRs
OpenAI and Epic integration brings AI healthcare into EHR workflows, connecting patient records with ChatGPT for Healthcare to advance research and patient care.
<p>Founded in 2004, Ametris (formerly ActiGraph) is a global digital health solutions provider transforming real-world patient data into validated clinical evidence. Our end-to-end platform combines advanced wearables, regulatory-aligned analytics, and expert scientific support across every phase of a clinical trial. We serve leading pharmaceutical, biotech, and public health research organizations worldwide, backed by two decades of experience and a collaborative, science-first approach.</p><p>In 2026, Ametris joined Signant Health, uniting wearable-derived digital outcome measures with industry-leading eCOA solutions to give sponsors a single partner for integrated evidence generation, combining continuous sensor data with patient-reported outcomes.</p>
Image
Clinical Development
<p><a href="https://www.medidata.com/en/">Medidata </a>has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata's <a href="https://www.medidata.com/en/experiences/study-experience/">Study</a>, <a href="https://www.medidata.com/en/experiences/patient-experience/">Patient</a>, and <a href="https://www.medidata.com/en/experiences/data-experience/">Data</a> Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at <a href="https://www.medidata.com/">www.medidata.com</a><strong>. </strong>Listen to our latest podcast, <a href="https://www.medidata.com/en/from-dreamers-to-disruptors-podcast/"><em>from Dreamers to Disruptors</em></a>,<strong> </strong>and follow us at @medidata-solutions on LinkedIn.</p>
Image
Clinical Development
<p>Caidya is a global, therapeutically focused drug development partner helping biotech and biopharma sponsors make smarter decisions, move faster, and advance together. Our connected teams combine scientific insight, operational expertise, and local knowledge across critical markets to generate actionable evidence and keep complex development programs moving forward.</p>
Image
HealthTech & AI
<p>We are rebuilding biotech for the AI era. When a breakthrough is delayed, the world waits.</p><p>Getting a molecule from discovery to patients, or a crop from lab to field, involves thousands of slow, manual, disconnected steps. AI has the potential to change this, compressing decades of R&D work into years. But that only happens when clean, structured scientific data and AI are built into how science gets done. </p><p>Benchling is the AI platform for biotech R&D. Scientists use Benchling to design experiments, capture structured data, and run AI agents and models directly in their workflows. Over 200,000 scientists around the world trust Benchling to power their most important work, from academic labs to Sanofi, Moderna, and more than half of the world's top 50 biopharma.</p>
Comments (0)